Paul Sekhri has joined Teva Pharmaceutical as group executive VP, global business development and chief strategy officer.
Based at the company’s headquarters in Israel, Sekhri joins at an important time for Teva as it prepares to expand its global footprint and develop its presence as a research-focused pharma company in addition to its existing reputation in generics.
Sekhri’s most recent role was as operating partner and head of the Biotech Ops Group at TPG Biotech, the life science venture arm of global private investment firm TPG.
Prior to this, he was president and CEO of Cerimon Pharmaceuticals, a biopharma focused on autoimmune conditions and pain management.
Other senior roles in his career include president and chief business officer of Ariad Pharmaceuticals and senior VP and head of global search and evaluation and M&A at Novartis.
Commenting on his new position, Sekhri said: “I believe my diverse background and perspectives with generic and pharmaceutical strategies and with a range of organisations, including multinational entities, small firms and venture groups, will contribute greatly to my ability to seek new relationships and support our partners as they advance innovations in healthcare.”